首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Whole-exome sequencing of T-B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants
【24h】

Whole-exome sequencing of T-B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants

机译:埃及婴儿的T-B +严重综合免疫缺陷的全面序列测序,JAK3主要和新型变种

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Severe combined immunodeficiency (SCID) is fatal if not treated with immune reconstitution. In Egypt, T-B+ SCID accounts for 38 center dot 5% of SCID diagnoses. An accurate genetic diagnosis is essential for choosing appropriate treatment modalities and for offering genetic counseling to the patient's family. The objectives of this study were to describe the clinical, immunological and molecular characteristics of a cohort of twenty Egyptian patients with T-B+ SCID. The initial diagnosis (based on clinical features and flow cytometry) was followed by molecular investigation (whole-exome sequencing). All patients had the classic clinical picture for SCID, including failure to thrive (n = 20), oral candidiasis (n = 17), persistent diarrhea (n = 14), pneumonia (n = 13), napkin dermatitis (n = 10), skin rash (n = 7), otitis media (n = 3) and meningitis (n = 2). The onset of manifestations was at the age of 2 center dot 4 +/- 1 center dot 6 months and diagnosis at the age of 6 center dot 7 +/- center dot 5 months, giving a diagnostic delay of 4 center dot 3 months. JAK3 gene variants were most frequent (n = 12) with three novel variants identified, followed by IL2R gamma variants (n = 6) with two novel variants. IL7R alpha and CD3 epsilon variants were found once, with a novel variant each. T-B+NK- SCID accounted for approximately 90% of the Egyptian patients with T-B+SCID. Of these T-B+NK- SCID cases, 60% were autosomal recessive syndromes caused by JAK3 mutations and 30% were X-linked syndromes. It might be useful to sequence the JAK3 gene (i.e. targeted Sanger sequencing) in all T-B+ SCID patients, especially after X-linked SCID has been ruled out. Hence, no more than 10% of T-B+ SCID patients might require next-generation for a molecular diagnosis.
机译:None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号